Johnson & Johnson JNJ 0.26% has tentatively agreed to pay about $700 million to settle an investigation brought by more than 40 states into the marketing of its talcum-based baby powder, a J&J ...

His research found that 18 out of 27 bottles of Johnson & Johnson's baby powder which were tested, or 67%, were positive for asbestos, while 18 out of 23 bottles of Johnson & Johnson's Shower to ...

His research found that 18 out of 27 bottles of Johnson & Johnson's baby powder which were tested, or 67%, were positive for asbestos, while 18 out of 23 bottles of Johnson & Johnson's Shower to ...

Johnson & Johnson has reached tentative agreement to resolve talc baby powder claims with more than 40 states, the world's biggest maker of health care products confirmed on Tuesday.

That includes Johnson's Baby Powder and Johnson & Johnson's Shower to Shower. The company decided to pull talc-based powders off the market in North America in 2020.

A US bankruptcy judge on Monday rejected Johnson & Johnson’s $10 billion proposal to end tens of thousands of lawsuits alleging that its baby powder and other talc products cause ovarian cancer ...

Illinois is one of 42 states, plus Washington, D.C., that alleged Johnson & Johnson deceptively promoted and misled consumers, in advertisements, about the safety of some of its talc powder products.

The complaint alleged that Pat Matthey's cancer was linked to the talc-based baby powder produced by Johnson & Johnson. A jury on Thursday ruled in the company's favor.

Now there is even more evidence that cosmetic talc, found in baby powder is causing this cancer [4] [5]. Mesothelioma is a rare form of cancer affecting only 0.3% of all cancer diagnoses in the USA.

In New Jersey, Johnson & Johnson was ordered to pay $186 million to four plaintiffs in a 2020 lawsuit that claimed baby powder caused their cancer.

In 2018, a Missouri court ordered Johnson & Johnson to pay nearly $4.7 billion to 22 women claiming asbestos in the company’s talcum powder was linked to their cases of ovarian cancer.